SlideShare a Scribd company logo
1 of 35
Download to read offline
Recent Advances and Remaining
Global Challenges in Control of
Meningococcal Disease
David S Stephens, MD
Emory University, Atlanta, USA
Advances and Challenges
• Neisseria meningitidis
• Changing Global Epidemiology
• Vaccine Impact
• Overall global declines in incidence but…..
• Meningococcal Evolution
• Challenges with 21ST Century Meningococcal Vaccines
“It's tough to make predictions, especially about the future” (and
especially about the meningococcus)
Neisseria
meningitidis
• Ancient Human
Commensal
• ~300 million->1 billion meningococcal
carriers worldwide
• 5%-25% of population
• Protective immunity- antibody
mediated serum bactericidal activity
• “Recent” Human Pathogen
• Historically ~550,000 – 1 million cases
of invasive disease (meningitis,
meningococcemia) worldwide
annually
• High mortality and morbidity
• Epidemics
Geneva - 1805
• Outbreak
• Rapid onset (hrs)
• Hemorrhagic eruption*
• Febrile course
• High mortality
• Gross inflammation of
the central nervous
system
- Vieusseux, Matthey
J. de Chirurgerie et Pharmacie
11:243, 1806
Epidemic Meningitis
Genomic Era- Clonal Complexes and
Fine Typing of N. meningitidis
• Genetic typing: multi-locus sequence type (MLST) and now whole
genome sequencing (http://pubmlst.org/neisseria/ based at the
University of Oxford, UK).
• 12 MLST clonal complexes cause almost all epidemic and endemic
invasive meningococcal disease:
• ST-5, ST-7 (serogroup A); ST-41/44, ST-32, ST-18, ST-8, ST-269, ST-35
(serogroup B); ST-11 (serogroup C or W); ST-23, ST-167 (serogroup Y); ST-181
(serogroup X).
• Large genetic islands, 8-32 kb: bacteriophage elements, restriction enzymes,
virulence proteins, potential toxins; CRISPR
• Genomic population of colonizing meningococci (MLST) considerably
more diverse
• Fine typing: fetA, porA, porB, fHbp
• Transformation: major mechanism of genetic exchange and
evolution, highly recombinogenic (>80:1 recombination:mutation)
Tettelin et al., Science 287: 1809,
10 March 2000
DynamicBiology of N. meningitidisLifeCycle
• Waves of introduction, carriage and transmission of clonal strains in populations-
emergence of new and disappearance of strains- immunity following carriage
• Changes in nasopharyngeal carriage of Neisseria meningitidis:
• Age- Adolescents
• Crowding (military recruits, Hajj, college dorms)
• Social Behavior (smoking, intimate kissing, pubs)
• Transformation/Recombination as the major
mechanism meningococcal evolution
• “Capsule switching”
• Microbiome effects
• Neisseria lactamica
• Carriage Density
• Environmental effects:
• Harmattan, humidity
Prevalence of Meningococcal Carriage
Christensen et al. Lancet ID
10:853, 2010
Changing Global Epidemiology
• Impact of New Meningococcal Vaccines- Importance of Herd Protection
• Targeted and “Widespread” Chemoprophylaxis
• Reduction of Risk Factors: Crowding, Smoke, Microbiome Changes
21st Century-MeningococcalVaccines
• Serogroup C polysaccharide protein conjugates*
• Introduced 1999-2000 (Protein: CRM197 or Tetanus Toxoid)
• Serogroup ACYW polysaccharide protein conjugates*
• Introduced 2005-2010
• Men ACYW Polysaccharide Diphtheria Toxoid Conjugate Vaccine
• Men ACYW Oligosaccharide Conjugate CRM197
• Serogroup A polysaccharide protein conjugate*
• Introduced 2010
• PsA–TT-serogroup A tetanus toxoid conjugate vaccine
• In Development- ACYWX conjugate (NmCV-5) 2020–2022
*Effect biology by prevention of new acquisitions at mucosal surfaces : Herd or community
protection
• Serogroup B outer membrane protein based vaccines
• Introduced 2013, 2014-2015
• fHBP, NadA , NHBA, outer membrane vesicles containing PorA P1.4
• Bivalent fHBp
21st Century Vaccinology: Different Human
Transcriptomic Responses to MPSV4 and MCV4
Nature Immunol 2014; 15:195-204
Herd Protection of Meningococcal Conjugate
Vaccines
• Accounts for ~one half of their effectiveness at preventing disease,
and has significantly enhanced the cost-effectiveness.
• Important consideration in strategies for vaccine introduction (mass
campaigns and emphasizing need for high vaccination uptake among
those with the highest transmission rates), implementation and
evaluation, cost-effectiveness
• Mucosal immunity-”knowledge gap”
• Mucosal immunoglobulins
• Transudation of high avidity serum IgG
• Th17 Immunity
Invasive Meningococcal Disease Incidence
• Africa: Meningitis Belt 2-7.5/100,000 (2017)
• South Africa 0.36/100,000
• Europe: 0.3-1.96/100,000 (2016/2017)
• Americas
• USA: 0.12 cases/100,000 (2016)
• Canada: 0.22/100,000 (2016)
• Mexico: 0.01-.04/100,000
• South America: 0.4-1/100,000
• Asia
• China: 0.2/100,000 (2015)
• Japan 0.03/100,000 (2014)
• South East Asia 0.1/100,000
• India: 0.32/100,000 (2014)
• Singapore O.1/100,000 (2015)
• Australia: 1.2/100,000 (2017)
• New Zealand: 1.6/100,000 (2017)
Guinea-Bissau
Cameroon
Chad
Ethiopia
Ghana
Kenya
Mauritania
Niger
Somalia
Sudan
Burkina
Faso
Mali
Gambia
Senegal
GuineaSierra
Leone Liberia BeninTogo
Djibouti
Central
African Rep.
NigeriaIvory
Coast
Uganda
-African meningococcal epidemics
Incidence 10-1000 cases/100,000
population- Serogroup A
-1996-1997 >300,000 cases, 30,000
deaths
- 88,199 meningococcal meningitis
cases in Africa in 2009
Harmattan
Sub-Saharan African Meningitis Belt
~1900
MVP, MenAfriCar, MenAfriNet
MenAfriVac (2000-2017) began
Burkina Faso 2010, Mali, Chad,
Niger, Benin, Ghana, Senegal,
Cameroon, Nigeria, Sudan, Gambia,
Ethiopia also have had campaigns.
>275 million doses in mass
vaccination campaigns (1-29 year
olds) that maximized herd protection,
Now being introduced in routine
childhood vaccine schedules
MenAfriCar: Welcome Trust/ Gates
Vaccine Effectiveness
MenAfriNet: Gates/ CDC
Post Vaccine Surveillance
Dec 6, 2010
Meningococcal Disease Africa
Borrow, R et al. Expert
Review of Vaccines, 16:4, 313-328
No lumbar puncture
MenAfriNet 2017 Weeks 1 – 26, 2017
EUROPE
Whittaker et al. The Epidemiology of Invasive meningococcal
Disease in EU/EEA countries, 2004–2014 Vaccine, Volume 35, Issue
16, 2017, 2034–2041
EUROPE
European Incidence- 2016
• England: 1/100,000 B, W, Y, C
• Scotland: 1.96/100,000 B, W, C
• Ireland: 1.51/100,000 B, C, W, Y
• Netherlands: 0.57/100,000 B, W, Y, C
• France: 0.78/100,000 B, C, Y, W
• Sweden: 0.6/100,000 W-Y, B ,C
• Finland: 0.35/100,000 B, Y, C, W
• Germany: 0.41/100,000 B, C, Y, W
• Portugal: 0.41/100,000 B, Y, W, C
• Italy: 0.39/100,000 B, C
• Greece: 0.5/100,000 B, Y, W
• Czech Republic: 0.4-0.5/100,000 B ,C ,Y, W
• Poland: 0.46/100,000 B, C, W, Y
• Russia: 0.43/100,000 B, C, A, W, Y
Australia Incidence
http://www.health.gov.au
Meningococcal Disease Incidence and Case-Fatality, U.S.,
1920-2002
Disappearance of Serogroup A Meningococcal Outbreaks
0
2
4
6
8
10
12
14
1921
1924
1927
1930
1933
1936
1939
1942
1945
1948
1951
1954
1957
1960
1963
1966
1969
1972
1975
1978
1981
1984
1987
1990
1993
1996
1999
2002
Year
Rateper100,000
population
0
10
20
30
40
50
60
70
80
Casefatalityratio
(%)
Incidence Case-fatality ratio
*
*
*
Disappearance of serogroup A carriage and
transmission.
Antibiotic effects on carriage?
Other environmental or ecology (micrbiome)
changes?
Decline of Meningococcal Disease Incidence United
States, 1994-2014
ACYW Conjugate VaccinesY outbreak
1Source: ABCs cases from 1993-2012 estimated to the U.S. population with 18% correction for under reporting
2National Immunization Survey – Teen; 2006-2012
0
20
40
60
80
100
0
0.1
0.2
0.3
0.4
0.5
0.6
1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014
CoveragewithMenACWYamong13-17year
olds2
Incidenceper100,0001
Serogroup B Serogroup C Serogroup Y
Clonal Expansion- Serogroup Y USA
• Serogroup Y (CC23) became leading cause of meningococcal disease
in US 1997-1999, reached a serogroup incidence of 0.52/100,000.
• During this time of increased incidence, CC23 was the predominant
carriage isolate found in >40% of carriers, indicating rapid spread in
the population.
J Infect Dis. (2002)
186:40-48.
U.S. Antibiotic Prescribing
Antibiotic Agent (top 5): Number of
Prescriptions in Millions (%) and
Prescriptions per 1,000 Persons
Azithromycin 51.5 166
Amoxicillin 51.4 166
Amoxicillin/clavulanate 21.5 70
Ciprofloxacin 20.4 66
Cephalexin 20.1 65
N Engl J Med 2013; 368:1461-1462
258 M outpatient antibiotic courses in 2010, 833 prescriptions per 1,000 Persons
Microbiome
• Neisseria lactamica
• Neisseria polysaccharea and Neisseria bergeri
• Bacillus pumilus polysaccharide cross-reactive with meningococcal group A
polysaccharide
• Escherichia coli capsule types K51 or K93
• The decrease in S. pneumoniae PCV7 VT serotypes,
increase in H. influenzae, especially NTHi, and S. aureus
• Antagonistic relationship between Corynebacterium
accolens and S. pneumoniae- microbiota-derived FFAs
MenAfriCar
Journal of Infection (2016), 72:667-677
mBio. 2016 Jan-Feb
Meningococcal Evolution
• Cyclic Changes in Incidence
• Y, W, X emergence; new B, C genotypes
• Emergence of nongroupables:
• cnl strains
• meningococcal urethritis
Serogroup X CC (ST)181
• 2000-2010, outbreaks of serogroup X meningitis occurred in Niger,
Uganda, Kenya, Ghana, Togo and Burkina Faso
• Show pattern of highly localized clonal waves, in affected districts,
other meningococcal serogroups are usually absent from disease
• Unique genes identified by WGS
Emerging Infectious Diseases (2016) 22:698-702
New Serogroup C Clades Africa and China
• Niger, Nigeria, CC-10217, PorA type P1.21-15,16 PorB 3–463 and
FetA type F1-7.
• Sequence type CC-4821 P1.7-2, 14 was first
reported in China in 2003, serogroups C and B
Emerg Infect Dis
(2016) 22:1762-1768
Genomics (2008)91: 78-87
US Nm urethritis clade, US_NmUC
• ~300 confirmed cases of meningococcal urethritis since
2014 due to same clade
• All US_NmUC isolates belong to the cc11.2/ET-15 lineage
(usually serogroup C)
• Identical fine type: PorA P1.5-1, 10-8; FetA F3-6; PorB 2-2
and express a unique fHBP allele.
• A common molecular fingerprint of the clade is an IS1301
element in the intergenic region separating the capsule
ctr-css operons and adjacent deletion of cssA/B/C and a
part of csc, encoding the serogroup C capsule polymerase.
MMWR(2016) 65:550-2
PNAS (2017) 114:4237-4242
CID (2017) 65:92-99
US N. meningitidis urethritis clade isolates distinct with respect to
lineage 11.2
Tzeng et al. PNAS 2017;114:4237-4242
US_NmUC
Clade
(A)
(B)
53-bp
aniAnorBgpxANMC1546 NMC1550
aniAnorBNGO1274 NGO1277
FA1090
CNM10 Nitric oxide reductase Nitrite reductase
CPH isolates
N. gonorrhoeae
N. meningitidis
CPH isolates
N. gonorrhoeae
N. meningitidis
N. lactamica
(C)
US_NmUC isolates Have Acquired the Gonococcal aniA/norB locus
Tzeng et al. PNAS
2017;114:4237-4242
Challenges with Meningococcal Vaccines
• Gaps in Vaccine Coverage (some B subtypes, X, nongroupable)
• Duration of Protection/Waning Efficacy and Effectiveness-Boosters
• High Risk Populations
• Global Vaccine Introduction and Policy Diversity by Country
• Cost and Cost-effectiveness
• Do we have a Path to a Gonococcal Vaccine?
Boosters for MenB Vaccines
Lancet Infectious Diseases (2017) 17:58-67
Eculizamab
• Complement component inhibitor licensed for:
• Paroxysmal nocturnal hemoglobinuria (PNH) (2007)
• Atypical hemolytic uremic syndrome (aHUS) (2011)
• Incidence of meningococcal disease 307/100,000 person-years
• 8 of 16 cases in US (50%) due to NG strains
• Vaccination provides at best incomplete protection to eculizumab
recipients
• Daily antibiotic chemoprophylaxis
Summary of Clusters/Outbreaks in the United States
Type Number
Max
Cases
Median
Cumulative
Attack Rate‡
Community
MSM# 2 22 12.4
Non-MSM# 20 14 1.0
Organization
University 9 10 47.6
Other† 10 8 444
Total 41 22 8.3
# MSM = Men who have sex with men
‡ Among clusters with known population size
† Includes correctional facility, health-care facility, high-school, sports camp, etc.
Effectiveness of a group B outer membrane vesicle
meningococcal vaccine against gonorrhoea in New Zealand: a
retrospective case-control study
Helen Petousis-Harris PhD , Janine Paynter PhD , Jane Morgan MD, Peter Saxton PhD ,
Barbara McArdle MCE , Prof Felicity Goodyear-Smith MD , Prof Steven Black MD
• Outer membrane vesicle meningococcal B vaccine (MeNZB) used in
New Zealand for previous serogroup B outbreak control
• Estimate vaccine effectiveness of MeNZB against gonorrhoea in 15-30
year olds after adjustment for ethnicity, deprivation, geographical
area, and sex was 31% (95% CI 21–39)
• OM vesicle also a component of MenB-4
390: 1603–1610, 30 September 2017
Next 20 years…..
• Global Control (<0.1/100,000) of Meningococcal Disease is Achievable with:
Timely Global Surveillance
Whole Genome Sequencing and Global Databases
Coordinated Strategies for Vaccine Introduction
Expanded Use of Quadrivalent or Pentavalent Polysaccharide- Protein Conjugate Vaccines
combined with B vaccine antigens
• Meningococcal Evolution will Continue
New Clades, Pathogenesis, Antibiotic Resistance
• Vaccine Challenges must be Addressed
Gaps in Vaccine Coverage (some B subtypes, X, nongroupable)
Duration of Protection/Waning Efficacy and Effectiveness- Boosters
Institutional and Community Outbreaks
High Risk Populations- Complement Deficiency
Global Vaccine Introduction and Policy Diversity by Country
Cost and Cost-effectiveness
“It's tough to make predictions, especially about the future”
“When you get to a fork in the road take it”
Yogi Berra

More Related Content

What's hot

Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
 
Carriage studies - what do they add? Human bacterial challenge experiments as...
Carriage studies - what do they add? Human bacterial challenge experiments as...Carriage studies - what do they add? Human bacterial challenge experiments as...
Carriage studies - what do they add? Human bacterial challenge experiments as...Meningitis Research Foundation
 
Current issues with meningococcal vaccine programmes in the UK
Current issues with meningococcal vaccine programmes in the UKCurrent issues with meningococcal vaccine programmes in the UK
Current issues with meningococcal vaccine programmes in the UKMeningitis Research Foundation
 
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Meningitis Research Foundation
 
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
 
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019Meningitis Research Foundation
 
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
 
Confidence in numbers; the evidence base for assessing thepublic health impac...
Confidence in numbers; the evidence base for assessing thepublic health impac...Confidence in numbers; the evidence base for assessing thepublic health impac...
Confidence in numbers; the evidence base for assessing thepublic health impac...Meningitis Research Foundation
 
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Meningitis Research Foundation
 
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017Meningitis Research Foundation
 
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...Meningitis Research Foundation
 
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Meningitis Research Foundation
 
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015Meningitis Research Foundation
 
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019Meningitis Research Foundation
 
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+Meningitis Research Foundation
 
Elimination of meningitis A epidemics in Africa; MenAfriVac future plans
Elimination of meningitis A epidemics in Africa; MenAfriVac future plansElimination of meningitis A epidemics in Africa; MenAfriVac future plans
Elimination of meningitis A epidemics in Africa; MenAfriVac future plansMeningitis Research Foundation
 
Meningococcal vaccine breakout
Meningococcal vaccine breakoutMeningococcal vaccine breakout
Meningococcal vaccine breakoutSunil Agarwalla
 

What's hot (20)

Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Dr Janine Paynter @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Carriage studies - what do they add? Human bacterial challenge experiments as...
Carriage studies - what do they add? Human bacterial challenge experiments as...Carriage studies - what do they add? Human bacterial challenge experiments as...
Carriage studies - what do they add? Human bacterial challenge experiments as...
 
Current issues with meningococcal vaccine programmes in the UK
Current issues with meningococcal vaccine programmes in the UKCurrent issues with meningococcal vaccine programmes in the UK
Current issues with meningococcal vaccine programmes in the UK
 
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Dr Nicole Basta @ @ MRF's Meningitis & Septicaemia in Children & Adults 2015
 
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
Prof Rick Malley @ Meningitis & Septicaemia in Children & Adults 2017
 
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019
Prof Rob Heyderman @ MRF's Meningitis and Septicaemia 2019
 
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Prof James Stuart @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and SepticaemiaDr Matt Coldiron @ MRF's Meningitis and Septicaemia
Dr Matt Coldiron @ MRF's Meningitis and Septicaemia
 
Confidence in numbers; the evidence base for assessing thepublic health impac...
Confidence in numbers; the evidence base for assessing thepublic health impac...Confidence in numbers; the evidence base for assessing thepublic health impac...
Confidence in numbers; the evidence base for assessing thepublic health impac...
 
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015 Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Marie Pierre @ MRF's Meningitis & Septicaemia in Children & Adults 2015
 
Novartis Group B Streptococcus vaccine programme
Novartis Group B Streptococcus vaccine programmeNovartis Group B Streptococcus vaccine programme
Novartis Group B Streptococcus vaccine programme
 
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
Dr Joanne Langley @ MRF's Meningitis & Septicaemia in children and Adults 2017
 
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...
Non-routine use of meningococcal vaccines in outbreaks and for individuals wi...
 
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
Helen Campbell @ MRF's Meningitis & Septicaemia in Children & Adults 2017
 
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
Prof Elizabeth Miller @ MRF's Meningitis & Septicaemia in Children & Adults 2015
 
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019
Dr Jayne Ellis @ MRF's Meningitis and Septicaemia 2019
 
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
Dr Matthew Colidron @ MRF's Meningitis & Septicaemia in Children & Adults 2017+
 
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
Prof Joy Lawn @ MRF's Meningitis and Septicaemia 2019
 
Elimination of meningitis A epidemics in Africa; MenAfriVac future plans
Elimination of meningitis A epidemics in Africa; MenAfriVac future plansElimination of meningitis A epidemics in Africa; MenAfriVac future plans
Elimination of meningitis A epidemics in Africa; MenAfriVac future plans
 
Meningococcal vaccine breakout
Meningococcal vaccine breakoutMeningococcal vaccine breakout
Meningococcal vaccine breakout
 

Similar to Prof David Stephens @ Meningitis & Septicaemia in Children & Adults

INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCE
INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCEINNOVATION AND IT'S IMPACT ON MEDICAL SCIENCE
INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCEAyush Keshav Singhal
 
Meningococcal Diseases and Vaccines.pptx
Meningococcal Diseases and Vaccines.pptxMeningococcal Diseases and Vaccines.pptx
Meningococcal Diseases and Vaccines.pptxdrquamrul
 
01 Cholera, Malaria, Tuberculosis (TB) and AIDS
01 Cholera, Malaria, Tuberculosis (TB) and AIDS01 Cholera, Malaria, Tuberculosis (TB) and AIDS
01 Cholera, Malaria, Tuberculosis (TB) and AIDSJaya Kumar
 
Complications of chronic otitis media
Complications of chronic otitis mediaComplications of chronic otitis media
Complications of chronic otitis mediaHimanshu Mishra
 
Current Issues in Foodborne Illness Caused by Staphylococcus aureus
Current Issues in Foodborne Illness Caused by Staphylococcus aureusCurrent Issues in Foodborne Illness Caused by Staphylococcus aureus
Current Issues in Foodborne Illness Caused by Staphylococcus aureusdedmark
 
Meningococcal disease
 Meningococcal disease Meningococcal disease
Meningococcal diseasethuphan95
 
A shot in the Dark-Final
A shot in the Dark-FinalA shot in the Dark-Final
A shot in the Dark-FinalMichal Tal
 
Supportive care in haemato oncology
Supportive  care in  haemato oncologySupportive  care in  haemato oncology
Supportive care in haemato oncologyHabibah Chaudhary
 
MENINGITIS.pptx
MENINGITIS.pptxMENINGITIS.pptx
MENINGITIS.pptxsakwa4
 
microbialdiseasesfor rimc -160303140348.pptx
microbialdiseasesfor rimc -160303140348.pptxmicrobialdiseasesfor rimc -160303140348.pptx
microbialdiseasesfor rimc -160303140348.pptxTrinityEducationDefe
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditisRahul Chalwade
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseasesSASMITANAYAK28
 
Definition of tuberculosis as scientific and practical problem
Definition of tuberculosis as scientific and practical problemDefinition of tuberculosis as scientific and practical problem
Definition of tuberculosis as scientific and practical problemOleksandr Ivashchenko
 
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRFebrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRDR Saqib Shah
 
Phthisiology_lecture_1.pdf
Phthisiology_lecture_1.pdfPhthisiology_lecture_1.pdf
Phthisiology_lecture_1.pdfNaushenMeinu
 

Similar to Prof David Stephens @ Meningitis & Septicaemia in Children & Adults (20)

INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCE
INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCEINNOVATION AND IT'S IMPACT ON MEDICAL SCIENCE
INNOVATION AND IT'S IMPACT ON MEDICAL SCIENCE
 
Meningococcal Diseases and Vaccines.pptx
Meningococcal Diseases and Vaccines.pptxMeningococcal Diseases and Vaccines.pptx
Meningococcal Diseases and Vaccines.pptx
 
01 Cholera, Malaria, Tuberculosis (TB) and AIDS
01 Cholera, Malaria, Tuberculosis (TB) and AIDS01 Cholera, Malaria, Tuberculosis (TB) and AIDS
01 Cholera, Malaria, Tuberculosis (TB) and AIDS
 
Complications of chronic otitis media
Complications of chronic otitis mediaComplications of chronic otitis media
Complications of chronic otitis media
 
Current Issues in Foodborne Illness Caused by Staphylococcus aureus
Current Issues in Foodborne Illness Caused by Staphylococcus aureusCurrent Issues in Foodborne Illness Caused by Staphylococcus aureus
Current Issues in Foodborne Illness Caused by Staphylococcus aureus
 
Meningococcal disease
 Meningococcal disease Meningococcal disease
Meningococcal disease
 
A shot in the Dark-Final
A shot in the Dark-FinalA shot in the Dark-Final
A shot in the Dark-Final
 
Supportive care in haemato oncology
Supportive  care in  haemato oncologySupportive  care in  haemato oncology
Supportive care in haemato oncology
 
Meningitis
MeningitisMeningitis
Meningitis
 
Meningitis
MeningitisMeningitis
Meningitis
 
MENINGITIS.pptx
MENINGITIS.pptxMENINGITIS.pptx
MENINGITIS.pptx
 
microbialdiseasesfor rimc -160303140348.pptx
microbialdiseasesfor rimc -160303140348.pptxmicrobialdiseasesfor rimc -160303140348.pptx
microbialdiseasesfor rimc -160303140348.pptx
 
Infective endocarditis
Infective endocarditisInfective endocarditis
Infective endocarditis
 
Meningitis in children
Meningitis in childrenMeningitis in children
Meningitis in children
 
Enteroviruses
EnterovirusesEnteroviruses
Enteroviruses
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
Definition of tuberculosis as scientific and practical problem
Definition of tuberculosis as scientific and practical problemDefinition of tuberculosis as scientific and practical problem
Definition of tuberculosis as scientific and practical problem
 
David Walker
David WalkerDavid Walker
David Walker
 
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIRFebrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
Febrile neutropenia by DR saqib ahmad shah PG radiation oncology SKIMS KASHMIR
 
Phthisiology_lecture_1.pdf
Phthisiology_lecture_1.pdfPhthisiology_lecture_1.pdf
Phthisiology_lecture_1.pdf
 

More from Meningitis Research Foundation (20)

Prof Rob Heyderman
Prof Rob HeydermanProf Rob Heyderman
Prof Rob Heyderman
 
Marco safadi
Marco safadiMarco safadi
Marco safadi
 
Brenda kwambana adams
Brenda kwambana adamsBrenda kwambana adams
Brenda kwambana adams
 
Professor Muhamed-Kheir Taha
Professor Muhamed-Kheir TahaProfessor Muhamed-Kheir Taha
Professor Muhamed-Kheir Taha
 
Potential use of MenABCWY vaccines
Potential use of MenABCWY vaccinesPotential use of MenABCWY vaccines
Potential use of MenABCWY vaccines
 
Dr william hanage
Dr william hanageDr william hanage
Dr william hanage
 
Dr Maria Deloria Knoll
Dr Maria Deloria KnollDr Maria Deloria Knoll
Dr Maria Deloria Knoll
 
Professor Nelesh govender
Professor Nelesh govender Professor Nelesh govender
Professor Nelesh govender
 
Professor Sir Andrew Pollard
Professor Sir Andrew PollardProfessor Sir Andrew Pollard
Professor Sir Andrew Pollard
 
Dr Manuel krone
Dr Manuel kroneDr Manuel krone
Dr Manuel krone
 
Yangyupei yang
Yangyupei yangYangyupei yang
Yangyupei yang
 
Dr Rodolfo villena
Dr Rodolfo villena  Dr Rodolfo villena
Dr Rodolfo villena
 
Sara katz
Sara katzSara katz
Sara katz
 
Dr Xin wang
Dr Xin wangDr Xin wang
Dr Xin wang
 
Professor Cal MacLennan
Professor Cal MacLennanProfessor Cal MacLennan
Professor Cal MacLennan
 
Dr Sami gottlieb
Dr Sami gottliebDr Sami gottlieb
Dr Sami gottlieb
 
Dr Lee hampton
Dr Lee hamptonDr Lee hampton
Dr Lee hampton
 
Professor Stefan flasche
Professor Stefan flascheProfessor Stefan flasche
Professor Stefan flasche
 
Professor Shrijana shrestha
Professor Shrijana shresthaProfessor Shrijana shrestha
Professor Shrijana shrestha
 
Professor David goldblatt
Professor David goldblattProfessor David goldblatt
Professor David goldblatt
 

Recently uploaded

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartMedicoseAcademics
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Anjali Parmar
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)Monika Kanwar
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumassuser144901
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxDr. Rabia Inam Gandapore
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxDr KHALID B.M
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Catherine Liao
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptdesktoppc
 
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRYDEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRYChsaiteja3
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryDr Simran Deepak Vangani
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgeryKafrELShiekh University
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthCatherine Liao
 
hypo and hyper thyroidism final lecture.pptx
hypo and hyper thyroidism  final lecture.pptxhypo and hyper thyroidism  final lecture.pptx
hypo and hyper thyroidism final lecture.pptxdr shahida
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionGolden Helix
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSuresh Kumar K
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingMedicoseAcademics
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale nowSherrylee83
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYDRPREETHIJAMESP
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Dr. Aryan (Anish Dhakal)
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxSergio Pinski
 

Recently uploaded (20)

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
CT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic traumaCT scan of penetrating abdominopelvic trauma
CT scan of penetrating abdominopelvic trauma
 
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptxThe Orbit & its contents by Dr. Rabia I. Gandapore.pptx
The Orbit & its contents by Dr. Rabia I. Gandapore.pptx
 
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptxCURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
CURRENT HEALTH PROBLEMS AND ITS SOLUTION BY AYURVEDA.pptx
 
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
Impact of cancers therapies on the loss in cardiac function, myocardial fffic...
 
World Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 pptWorld Hypertension Day 17th may 2024 ppt
World Hypertension Day 17th may 2024 ppt
 
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRYDEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
DEVELOPMENT OF OCCLUSION IN PEDIATRIC DENTISTRY
 
Factors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric DentistryFactors Affecting child behavior in Pediatric Dentistry
Factors Affecting child behavior in Pediatric Dentistry
 
Retinal consideration in cataract surgery
Retinal consideration in cataract surgeryRetinal consideration in cataract surgery
Retinal consideration in cataract surgery
 
Effects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial healthEffects of vaping e-cigarettes on arterial health
Effects of vaping e-cigarettes on arterial health
 
hypo and hyper thyroidism final lecture.pptx
hypo and hyper thyroidism  final lecture.pptxhypo and hyper thyroidism  final lecture.pptx
hypo and hyper thyroidism final lecture.pptx
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptxSURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
SURGICAL ANATOMY OF ORAL IMPLANTOLOGY.pptx
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
5CL-ADB powder supplier 5cl adb 5cladba 5cl raw materials vendor on sale now
 
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHYTUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
TUBERCULINUM-2.BHMS.MATERIA MEDICA.HOMOEOPATHY
 
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
Book Trailer: PGMEE in a Nutshell (CEE MD/MS PG Entrance Examination)
 
A thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptxA thorough review of supernormal conduction.pptx
A thorough review of supernormal conduction.pptx
 

Prof David Stephens @ Meningitis & Septicaemia in Children & Adults

  • 1. Recent Advances and Remaining Global Challenges in Control of Meningococcal Disease David S Stephens, MD Emory University, Atlanta, USA
  • 2. Advances and Challenges • Neisseria meningitidis • Changing Global Epidemiology • Vaccine Impact • Overall global declines in incidence but….. • Meningococcal Evolution • Challenges with 21ST Century Meningococcal Vaccines “It's tough to make predictions, especially about the future” (and especially about the meningococcus)
  • 3. Neisseria meningitidis • Ancient Human Commensal • ~300 million->1 billion meningococcal carriers worldwide • 5%-25% of population • Protective immunity- antibody mediated serum bactericidal activity • “Recent” Human Pathogen • Historically ~550,000 – 1 million cases of invasive disease (meningitis, meningococcemia) worldwide annually • High mortality and morbidity • Epidemics
  • 4. Geneva - 1805 • Outbreak • Rapid onset (hrs) • Hemorrhagic eruption* • Febrile course • High mortality • Gross inflammation of the central nervous system - Vieusseux, Matthey J. de Chirurgerie et Pharmacie 11:243, 1806 Epidemic Meningitis
  • 5. Genomic Era- Clonal Complexes and Fine Typing of N. meningitidis • Genetic typing: multi-locus sequence type (MLST) and now whole genome sequencing (http://pubmlst.org/neisseria/ based at the University of Oxford, UK). • 12 MLST clonal complexes cause almost all epidemic and endemic invasive meningococcal disease: • ST-5, ST-7 (serogroup A); ST-41/44, ST-32, ST-18, ST-8, ST-269, ST-35 (serogroup B); ST-11 (serogroup C or W); ST-23, ST-167 (serogroup Y); ST-181 (serogroup X). • Large genetic islands, 8-32 kb: bacteriophage elements, restriction enzymes, virulence proteins, potential toxins; CRISPR • Genomic population of colonizing meningococci (MLST) considerably more diverse • Fine typing: fetA, porA, porB, fHbp • Transformation: major mechanism of genetic exchange and evolution, highly recombinogenic (>80:1 recombination:mutation) Tettelin et al., Science 287: 1809, 10 March 2000
  • 6. DynamicBiology of N. meningitidisLifeCycle • Waves of introduction, carriage and transmission of clonal strains in populations- emergence of new and disappearance of strains- immunity following carriage • Changes in nasopharyngeal carriage of Neisseria meningitidis: • Age- Adolescents • Crowding (military recruits, Hajj, college dorms) • Social Behavior (smoking, intimate kissing, pubs) • Transformation/Recombination as the major mechanism meningococcal evolution • “Capsule switching” • Microbiome effects • Neisseria lactamica • Carriage Density • Environmental effects: • Harmattan, humidity Prevalence of Meningococcal Carriage Christensen et al. Lancet ID 10:853, 2010
  • 7. Changing Global Epidemiology • Impact of New Meningococcal Vaccines- Importance of Herd Protection • Targeted and “Widespread” Chemoprophylaxis • Reduction of Risk Factors: Crowding, Smoke, Microbiome Changes
  • 8. 21st Century-MeningococcalVaccines • Serogroup C polysaccharide protein conjugates* • Introduced 1999-2000 (Protein: CRM197 or Tetanus Toxoid) • Serogroup ACYW polysaccharide protein conjugates* • Introduced 2005-2010 • Men ACYW Polysaccharide Diphtheria Toxoid Conjugate Vaccine • Men ACYW Oligosaccharide Conjugate CRM197 • Serogroup A polysaccharide protein conjugate* • Introduced 2010 • PsA–TT-serogroup A tetanus toxoid conjugate vaccine • In Development- ACYWX conjugate (NmCV-5) 2020–2022 *Effect biology by prevention of new acquisitions at mucosal surfaces : Herd or community protection • Serogroup B outer membrane protein based vaccines • Introduced 2013, 2014-2015 • fHBP, NadA , NHBA, outer membrane vesicles containing PorA P1.4 • Bivalent fHBp
  • 9. 21st Century Vaccinology: Different Human Transcriptomic Responses to MPSV4 and MCV4 Nature Immunol 2014; 15:195-204
  • 10. Herd Protection of Meningococcal Conjugate Vaccines • Accounts for ~one half of their effectiveness at preventing disease, and has significantly enhanced the cost-effectiveness. • Important consideration in strategies for vaccine introduction (mass campaigns and emphasizing need for high vaccination uptake among those with the highest transmission rates), implementation and evaluation, cost-effectiveness • Mucosal immunity-”knowledge gap” • Mucosal immunoglobulins • Transudation of high avidity serum IgG • Th17 Immunity
  • 11. Invasive Meningococcal Disease Incidence • Africa: Meningitis Belt 2-7.5/100,000 (2017) • South Africa 0.36/100,000 • Europe: 0.3-1.96/100,000 (2016/2017) • Americas • USA: 0.12 cases/100,000 (2016) • Canada: 0.22/100,000 (2016) • Mexico: 0.01-.04/100,000 • South America: 0.4-1/100,000 • Asia • China: 0.2/100,000 (2015) • Japan 0.03/100,000 (2014) • South East Asia 0.1/100,000 • India: 0.32/100,000 (2014) • Singapore O.1/100,000 (2015) • Australia: 1.2/100,000 (2017) • New Zealand: 1.6/100,000 (2017)
  • 12. Guinea-Bissau Cameroon Chad Ethiopia Ghana Kenya Mauritania Niger Somalia Sudan Burkina Faso Mali Gambia Senegal GuineaSierra Leone Liberia BeninTogo Djibouti Central African Rep. NigeriaIvory Coast Uganda -African meningococcal epidemics Incidence 10-1000 cases/100,000 population- Serogroup A -1996-1997 >300,000 cases, 30,000 deaths - 88,199 meningococcal meningitis cases in Africa in 2009 Harmattan Sub-Saharan African Meningitis Belt ~1900
  • 13. MVP, MenAfriCar, MenAfriNet MenAfriVac (2000-2017) began Burkina Faso 2010, Mali, Chad, Niger, Benin, Ghana, Senegal, Cameroon, Nigeria, Sudan, Gambia, Ethiopia also have had campaigns. >275 million doses in mass vaccination campaigns (1-29 year olds) that maximized herd protection, Now being introduced in routine childhood vaccine schedules MenAfriCar: Welcome Trust/ Gates Vaccine Effectiveness MenAfriNet: Gates/ CDC Post Vaccine Surveillance Dec 6, 2010
  • 14. Meningococcal Disease Africa Borrow, R et al. Expert Review of Vaccines, 16:4, 313-328
  • 15. No lumbar puncture MenAfriNet 2017 Weeks 1 – 26, 2017
  • 16. EUROPE Whittaker et al. The Epidemiology of Invasive meningococcal Disease in EU/EEA countries, 2004–2014 Vaccine, Volume 35, Issue 16, 2017, 2034–2041 EUROPE
  • 17. European Incidence- 2016 • England: 1/100,000 B, W, Y, C • Scotland: 1.96/100,000 B, W, C • Ireland: 1.51/100,000 B, C, W, Y • Netherlands: 0.57/100,000 B, W, Y, C • France: 0.78/100,000 B, C, Y, W • Sweden: 0.6/100,000 W-Y, B ,C • Finland: 0.35/100,000 B, Y, C, W • Germany: 0.41/100,000 B, C, Y, W • Portugal: 0.41/100,000 B, Y, W, C • Italy: 0.39/100,000 B, C • Greece: 0.5/100,000 B, Y, W • Czech Republic: 0.4-0.5/100,000 B ,C ,Y, W • Poland: 0.46/100,000 B, C, W, Y • Russia: 0.43/100,000 B, C, A, W, Y
  • 19. Meningococcal Disease Incidence and Case-Fatality, U.S., 1920-2002 Disappearance of Serogroup A Meningococcal Outbreaks 0 2 4 6 8 10 12 14 1921 1924 1927 1930 1933 1936 1939 1942 1945 1948 1951 1954 1957 1960 1963 1966 1969 1972 1975 1978 1981 1984 1987 1990 1993 1996 1999 2002 Year Rateper100,000 population 0 10 20 30 40 50 60 70 80 Casefatalityratio (%) Incidence Case-fatality ratio * * * Disappearance of serogroup A carriage and transmission. Antibiotic effects on carriage? Other environmental or ecology (micrbiome) changes?
  • 20. Decline of Meningococcal Disease Incidence United States, 1994-2014 ACYW Conjugate VaccinesY outbreak 1Source: ABCs cases from 1993-2012 estimated to the U.S. population with 18% correction for under reporting 2National Immunization Survey – Teen; 2006-2012 0 20 40 60 80 100 0 0.1 0.2 0.3 0.4 0.5 0.6 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 CoveragewithMenACWYamong13-17year olds2 Incidenceper100,0001 Serogroup B Serogroup C Serogroup Y
  • 21. Clonal Expansion- Serogroup Y USA • Serogroup Y (CC23) became leading cause of meningococcal disease in US 1997-1999, reached a serogroup incidence of 0.52/100,000. • During this time of increased incidence, CC23 was the predominant carriage isolate found in >40% of carriers, indicating rapid spread in the population. J Infect Dis. (2002) 186:40-48.
  • 22. U.S. Antibiotic Prescribing Antibiotic Agent (top 5): Number of Prescriptions in Millions (%) and Prescriptions per 1,000 Persons Azithromycin 51.5 166 Amoxicillin 51.4 166 Amoxicillin/clavulanate 21.5 70 Ciprofloxacin 20.4 66 Cephalexin 20.1 65 N Engl J Med 2013; 368:1461-1462 258 M outpatient antibiotic courses in 2010, 833 prescriptions per 1,000 Persons
  • 23. Microbiome • Neisseria lactamica • Neisseria polysaccharea and Neisseria bergeri • Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide • Escherichia coli capsule types K51 or K93 • The decrease in S. pneumoniae PCV7 VT serotypes, increase in H. influenzae, especially NTHi, and S. aureus • Antagonistic relationship between Corynebacterium accolens and S. pneumoniae- microbiota-derived FFAs MenAfriCar Journal of Infection (2016), 72:667-677 mBio. 2016 Jan-Feb
  • 24. Meningococcal Evolution • Cyclic Changes in Incidence • Y, W, X emergence; new B, C genotypes • Emergence of nongroupables: • cnl strains • meningococcal urethritis
  • 25. Serogroup X CC (ST)181 • 2000-2010, outbreaks of serogroup X meningitis occurred in Niger, Uganda, Kenya, Ghana, Togo and Burkina Faso • Show pattern of highly localized clonal waves, in affected districts, other meningococcal serogroups are usually absent from disease • Unique genes identified by WGS Emerging Infectious Diseases (2016) 22:698-702
  • 26. New Serogroup C Clades Africa and China • Niger, Nigeria, CC-10217, PorA type P1.21-15,16 PorB 3–463 and FetA type F1-7. • Sequence type CC-4821 P1.7-2, 14 was first reported in China in 2003, serogroups C and B Emerg Infect Dis (2016) 22:1762-1768 Genomics (2008)91: 78-87
  • 27. US Nm urethritis clade, US_NmUC • ~300 confirmed cases of meningococcal urethritis since 2014 due to same clade • All US_NmUC isolates belong to the cc11.2/ET-15 lineage (usually serogroup C) • Identical fine type: PorA P1.5-1, 10-8; FetA F3-6; PorB 2-2 and express a unique fHBP allele. • A common molecular fingerprint of the clade is an IS1301 element in the intergenic region separating the capsule ctr-css operons and adjacent deletion of cssA/B/C and a part of csc, encoding the serogroup C capsule polymerase. MMWR(2016) 65:550-2 PNAS (2017) 114:4237-4242 CID (2017) 65:92-99
  • 28. US N. meningitidis urethritis clade isolates distinct with respect to lineage 11.2 Tzeng et al. PNAS 2017;114:4237-4242 US_NmUC Clade
  • 29. (A) (B) 53-bp aniAnorBgpxANMC1546 NMC1550 aniAnorBNGO1274 NGO1277 FA1090 CNM10 Nitric oxide reductase Nitrite reductase CPH isolates N. gonorrhoeae N. meningitidis CPH isolates N. gonorrhoeae N. meningitidis N. lactamica (C) US_NmUC isolates Have Acquired the Gonococcal aniA/norB locus Tzeng et al. PNAS 2017;114:4237-4242
  • 30. Challenges with Meningococcal Vaccines • Gaps in Vaccine Coverage (some B subtypes, X, nongroupable) • Duration of Protection/Waning Efficacy and Effectiveness-Boosters • High Risk Populations • Global Vaccine Introduction and Policy Diversity by Country • Cost and Cost-effectiveness • Do we have a Path to a Gonococcal Vaccine?
  • 31. Boosters for MenB Vaccines Lancet Infectious Diseases (2017) 17:58-67
  • 32. Eculizamab • Complement component inhibitor licensed for: • Paroxysmal nocturnal hemoglobinuria (PNH) (2007) • Atypical hemolytic uremic syndrome (aHUS) (2011) • Incidence of meningococcal disease 307/100,000 person-years • 8 of 16 cases in US (50%) due to NG strains • Vaccination provides at best incomplete protection to eculizumab recipients • Daily antibiotic chemoprophylaxis
  • 33. Summary of Clusters/Outbreaks in the United States Type Number Max Cases Median Cumulative Attack Rate‡ Community MSM# 2 22 12.4 Non-MSM# 20 14 1.0 Organization University 9 10 47.6 Other† 10 8 444 Total 41 22 8.3 # MSM = Men who have sex with men ‡ Among clusters with known population size † Includes correctional facility, health-care facility, high-school, sports camp, etc.
  • 34. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study Helen Petousis-Harris PhD , Janine Paynter PhD , Jane Morgan MD, Peter Saxton PhD , Barbara McArdle MCE , Prof Felicity Goodyear-Smith MD , Prof Steven Black MD • Outer membrane vesicle meningococcal B vaccine (MeNZB) used in New Zealand for previous serogroup B outbreak control • Estimate vaccine effectiveness of MeNZB against gonorrhoea in 15-30 year olds after adjustment for ethnicity, deprivation, geographical area, and sex was 31% (95% CI 21–39) • OM vesicle also a component of MenB-4 390: 1603–1610, 30 September 2017
  • 35. Next 20 years….. • Global Control (<0.1/100,000) of Meningococcal Disease is Achievable with: Timely Global Surveillance Whole Genome Sequencing and Global Databases Coordinated Strategies for Vaccine Introduction Expanded Use of Quadrivalent or Pentavalent Polysaccharide- Protein Conjugate Vaccines combined with B vaccine antigens • Meningococcal Evolution will Continue New Clades, Pathogenesis, Antibiotic Resistance • Vaccine Challenges must be Addressed Gaps in Vaccine Coverage (some B subtypes, X, nongroupable) Duration of Protection/Waning Efficacy and Effectiveness- Boosters Institutional and Community Outbreaks High Risk Populations- Complement Deficiency Global Vaccine Introduction and Policy Diversity by Country Cost and Cost-effectiveness “It's tough to make predictions, especially about the future” “When you get to a fork in the road take it” Yogi Berra